Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.52 |
| ▸ | FAP | Q12884 | 3/20 | 0.52 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23314580 | 0.91 | PREP (0.61) | PREPFAPDPP4DPP8DPP9 | |
| SCHEMBL17282610 | 0.89 | PREP (0.56) | PREPFAPDPP4DPP8DPP9 | |
| SCHEMBL18681193 | 0.86 | PREP (0.38) | PREPFAPDPP4DPP8DPP9 | |
| SCHEMBL18681135 | 0.84 | PREP (0.38) | PREPFAPDPP4DPP8DPP9 | |
| SCHEMBL17282592 | 0.80 | PREP (0.49) | PREPFAPPIN1DPP4DPP8 | |
| SCHEMBL16219075 | 0.79 | DPP4 (0.39) | PREPFAPDPP4DPP8DPP9 | |
| SCHEMBL26616440 | 0.78 | PREP (0.47) | PREPFAPACE2ACEREN | |
| SCHEMBL26616445 | 0.78 | PREP (0.47) | PREPFAPACE2ACEREN | |
| SCHEMBL26616435 | 0.78 | PREP (0.47) | PREPFAPACE2ACEREN | |
| SCHEMBL17282584 | 0.77 | PREP (0.64) | PREPFAPDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145944-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2015179441-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | PREP 16/4885FAP 206/4885PIN1 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.